

AC/TMH:gte:dv 04/20/05 4239-67016-02 371407  
PATENT

EXPRESS MAIL LABEL NO. EV510808507US  
DATE OF DEPOSIT: April 21, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Berzofsky *et al.*

**Application No.** \_\_\_\_\_

**Filed:** Herewith

**Confirmation No.** \_\_\_\_\_

**For:** METHODS TO PREVENT TUMOR  
RECURRENCE BY BLOCKADE OF TGF-  
BETA

**Examiner:** \_\_\_\_\_

**Art Unit:** \_\_\_\_\_

**Attorney Reference No.** 4239-67016-02

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(2)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

10/532374

2 Rec'd PCT/PTC 21 APR 2005

AC/TMH:gte:dv 04/20/05 4239-67016-02 371407  
PATENT


EXPRESS MAIL LABEL NO. EV510808507US  
DATE OF DEPOSIT: April 21, 2005

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, authorization to charge any such fees to Deposit Account No. 02-4550 is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Anne Carlson, Ph.D.  
Registration No. 47,472

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

JUL 12 Rec'd PCT/PTC 21 APR 2005

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Attorney Docket Number	4239-67016-02
Application Number	
Filed	Herewith
First Named Inventor	Berzofsky
Art Unit	
Examiner Name	

**U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,772,998	30 June 1998	Dasch <i>et al.</i>
		5,844,099	1 Dec 1998	Stahl <i>et al.</i>
		6,046,165	4 April 2000	Laughon <i>et al.</i>
		6,090,383	18 July 2000	Dasch <i>et al.</i>
		6,120,763	19 Sept 2000	Fakhrai <i>et al.</i>
		6,383,733	7 May 2002	Beug <i>et al.</i>
		6,410,043	25 June 2002	Steiner <i>et al.</i>
		6,419,928	16 July 2002	Dasch <i>et al.</i>
		2003/0125251	3 July 2003	Wakefield <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	WO 97/49421	31 Dec 1997	Regents of the University of Minnesota
		WIPO/PCT	WO 99/63975	16 Dec 1999	Biagnostick Gesellschaft für Biomolekulare Diagnostik MBH

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		AHLERS <i>et al.</i> , "A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte / macrophage colony-stimulating factor and CD40L," <i>PNAS</i> 99(2):13020-13025, October 1, 2002

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/532374

312 Rec'd PCT/PTC 21 APR 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Attorney Docket Number	4239-67016-02
			Application Number	
			Filed	Herewith
			First Named Inventor	Berzofsky
			Art Unit	
			Examiner Name	
		AKHURST <i>et al.</i> , "Genetic Events and the Role of TGF $\beta$ in Epithelial Tumour Progression," <i>J. Pathol.</i> 187:82-90, 1999		
		AKHURST, "TGF-beta antagonists: why suppress a tumor suppressor?" <i>J. Clin. Invest.</i> 109:1533-1536, 2002		
		ARTEAGA <i>et al.</i> , "Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression," <i>J. Clin. Invest.</i> 92:2569-2576, 1993		
		AZUMA <i>et al.</i> , "Lack of Expression of Transforming Growth Factor- $\beta$ Type II Receptor Associated with Malignant Progression in Human Salivary Gland Cell Clones," <i>Int. J. Cancer</i> 66:802-805, 1996		
		BLOBE <i>et al.</i> , "Role of Transforming Growth Factor $\beta$ in Human Disease," <i>New Eng. J. Med.</i> 342:1350-1358, 2000		
		BOLLARD <i>et al.</i> , "Adapting a Transforming Growth Factor Beta-Related Tumor Protection Strategy to Enhance Antitumor Immunity," <i>Blood</i> 99(9):3179-3187, 2002		
		BORDER <i>et al.</i> , "Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease," <i>Nature</i> 360:361-364, 1992		
		BÖTTINGER <i>et al.</i> , "The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice," <i>PNAS USA</i> 93:5877-5882, 1996		
		BRISTOW <i>et al.</i> , "Altered Expression of Transforming Growth Factor-Beta Ligands and Receptors in Primary and Recurrent Ovarian Carcinoma," <i>Cancer</i> 85(3):658-668, 1999 (abstract only)		
		BURMESTER <i>et al.</i> , "Characterization of distinct functional domains of transforming growth factor $\beta$ ," <i>Proc. Natl. Acad. Sci. USA</i> 90:8628-8632, 1993		
		CAVER <i>et al.</i> , "Intracellular Demonstration of Active TGF $\beta$ 1 in B Cells and Plasma Cells of Autoimmune Mice," <i>J. Clin. Invest.</i> 11:2496-2506, 1996		
		DASCH <i>et al.</i> , "Monoclonal Antibodies Recognizing Transforming Growth Factor- $\beta$ , Bioactivity Neutralization and Transforming Growth Factor $\beta$ 2 Affinity Purification," <i>J. Immunol.</i> 142(5):1536-1541, 1989		
		EVANGELOU <i>et al.</i> , "Down-Regulation of Transforming Growth Factor $\beta$ Receptors by Androgen in Ovarian Cancer Cells," <i>Cancer Res.</i> 60:929-935, 2000		
		FRIEDMAN <i>et al.</i> , "High Levels of Transforming Growth Factor Beta 1 Correlate with Disease Progression in Human Colon Cancer," <i>Cancer Epidemiol. Biomarkers Prev.</i> 4(5):549-554, 1995 (abstract only)		

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/532374

12 Rec'd PCT/P: 21 APR 2005

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Attorney Docket Number	4239-67016-02
Application Number	
Filed	Herewith
First Named Inventor	Berzofsky
Art Unit	
Examiner Name	

	GAZZANIGA <i>et al.</i> , "High Levels of Transforming Factor-Alpha (TGF-alpha) mRNA May Predict Local Relapses in Early Stage Urinary Bladder Cancer," <i>Eur. J. Cancer</i> 34(6):934-936, 1998 (abstract only)
	GEORGE <i>et al.</i> , "In vivo inhibition of rat stellate cell activation by soluble transforming growth factor $\beta$ type II receptor: A potential new therapy for hepatic fibrosis," <i>PNAS</i> 96(22):12719-12724, 1999
	GOLD, "The Role for Transforming Growth Factor- $\beta$ (TGF- $\beta$ ) in Human Cancer," <i>Crit. Rev. Oncogen.</i> 10:303-360, 1999
	GORELIK <i>et al.</i> , "Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor- $\beta$ Signaling in T Cells," <i>Nature Medicine</i> 7(10):1118-1122, 2001 (abstract only)
	GOLGHER <i>et al.</i> , "Depletion of CD25 regulatory cells uncovers immune responses to shared murine tumor rejection antigens," <i>Eur. J. Immunol.</i> 32:3267-3275, 2002
	GUO <i>et al.</i> , "Down-Regulation of Protein and mRNA Expression for Transforming Growth Factor- $\beta$ (TGF- $\beta$ 1) Type I and Type II Receptors in Human Prostate Cancer," <i>Int. J. Cancer</i> 71:573-579, 1997
	ISAKA <i>et al.</i> , "Gene therapy by transforming growth factor- $\beta$ receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis," <i>Kidney Internat.</i> 55:465-475, 1999
	KANTO <i>et al.</i> , "Neutralization of Transforming Growth Factor Beta 1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction in Vitro," <i>J. Clin. Immunol.</i> 17(6):462-471, 1997 (abstract only)
	KOMESLI <i>et al.</i> , "Chimeric extracellular domain of type II transforming growth factor (TGF)- $\beta$ receptor fused to the Fc region of human immunoglobulin as a TGF- $\beta$ antagonist," <i>Eur. J. Biochem.</i> 254:505-513, 1998
	LEE <i>et al.</i> , "Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor $\beta_1$ ," <i>J. Exp. Med.</i> 194(6):809-821, 2001
	LEE <i>et al.</i> , "The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor- $\beta$ Signaling by Blocking Binding of the Smad Complex to Its Target Sequence," <i>J. Biological Chemistry</i> 277(41):38557-38564, October 11, 2002
	LUCAS <i>et al.</i> , "The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA." <i>J. Immunol.</i> 145(5):1415-1422, September 1, 1990 (abstract only)

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

10/532374

2005 Rec'd PCT/PTC 21 APR 2005  
DATE OF DEPOSIT: April 21, 2005

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-67016-02
		Application Number	
		Filed	Herewith
		First Named Inventor	Berzofsky
		Art Unit	
		Examiner Name	
		MAO <i>et al.</i> , "Immunotherapy with Low-dose Interleukin-2 and Anti-transforming Growth Factor- $\beta$ Antibody in a Murine Tumor Model," <i>Cancer Biotherapy</i> 9(4):317-327, 1994	
		MASSAGUÉ <i>et al.</i> , "Controlling TGF-beta signaling," <i>Genes &amp; Dev.</i> 14:627-644, 2000	
		MASSAGUÉ <i>et al.</i> , "Transcriptional Control by the TGF- $\beta$ /Smad Signaling System," <i>EMBO J.</i> 19(8):1745-1754, 2000	
		MATSUI <i>et al.</i> , "A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL," <i>J. Immunol.</i> 163:184-193, 1999.	
		MCEARCHERN <i>et al.</i> , "Invasion and metastasis of a mammary tumor involves TGF-beta signaling," <i>Int. J. Cancer</i> 91:76-82, 2001	
		MOUSTAKAS <i>et al.</i> , "Smad Regulation in TGF- $\beta$ Signal Transduction," <i>J. Cell Sci.</i> 114:4359-4369, 2001	
		MULÉ <i>et al.</i> , "Transforming Growth Factor-Beta Inhibits the in Vitro Generation of Lymphokine-Activated Killer Cells and Cytotoxic T Cells," <i>Cancer Immunol. Immunother.</i> 26:95-100, 1988	
		MUROAKA <i>et al.</i> , "Blockade of TGF- $\beta$ Inhibits Mammary Tumor Cell Viability, Migration, and Metastases," <i>J. Clin. Invest.</i> 109(12):1551-1559, 2002	
		OFT <i>et al.</i> , "TGF $\beta$ signaling is necessary for carcinoma cell invasiveness and metastasis," <i>Curr. Biol.</i> 8:1243-1252, 1998	
		PARK <i>et al.</i> , "Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4(+) NKT regulatory cells and IL-13," <i>Int. J. Cancer</i> 114:80-87, 2005	
		QIAN <i>et al.</i> , "Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor $\beta$ on endothelial cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:6290-6294, 1992	
		QIAN <i>et al.</i> , "Binding Affinity of Transforming Growth Factor- $\beta$ for Its Type II Receptor Is Determined by the C-terminal Region of the Molecule," <i>J. Biol. Chem.</i> 271(48):30656-30662, 1996	
		SEO <i>et al.</i> , "Depletion of IL-10- and TGF- $\beta$ -Producing Regulatory $\gamma\delta$ T Cells by Administering a Daunomycin-Conjugated Specific Monoclonal Antibody in Early Tumor Lesions Augments the Activity of CTLs and NK Cells," <i>J. Immunol.</i> 163:242-249, 1999	
		SHARIAT <i>et al.</i> , "Preoperative Plasma Levels of Transforming Growth Factor Beta(1) (TGF-beta(1)) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy," <i>J. Clin. Oncol.</i> 19(11):2856-2864, 2001 (abstract only)	

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Attorney Docket Number	4239-67016-02
			Application Number	
			Filed	Herewith
			First Named Inventor	Berzofsky
			Art Unit	
			Examiner Name	
		SMITH <i>et al.</i> , "Soluble Transforming Growth Factor- $\beta$ Type II Receptor Inhibits Negative Remodeling, Fibroblast Transdifferentiation, and Intimal Lesion Formation But Not Endothelial Growth," <i>Circ. Res.</i> 84:1212-1222, 1999		
		TERABE <i>et al.</i> , "NKT Cell-Mediated Repression of Tumor Immunosurveillance by IL-13 and the IL-4R-STAT6 Pathway," <i>Nat Immunol</i> 1(6):515-520, 2000		
		TSANG <i>et al.</i> , "Characterization of Recombinant Soluble Human Transforming Growth Factor- $\beta$ Receptor Type II (rhTGF- $\beta$ sRII)," <i>Cytokine</i> 7(5):389-397, 1995		
		TSUSHIMA <i>et al.</i> , "Circulating Transforming Growth Factor $\beta_1$ as a Predictor of Liver Metastasis after Resection in Colorectal Cancer," <i>Clin. Cancer Res.</i> 7:1258-1262, 2001		
		TURCO <i>et al.</i> , "Overexpression of Transforming Growth Factor 140969-Type II Receptor Reduces Tumorigenicity and Metastatic Potential of K-ras-Transformed Thyroid Cells," <i>Int. J. Cancer</i> 80:85-91, 1999		
		UENO <i>et al.</i> , "A Soluble Transforming Growth Factor $\beta$ Receptor Expressed in Muscle Prevents Liver Fibrogenesis and Dysfunction in Rats," <i>Human Gene Ther.</i> 11:33-42, 2000		
		WANG <i>et al.</i> , "Reduction of bleomycin induced lung fibrosis by transforming growth factor $\beta$ soluble receptor in hamsters," <i>Thorax</i> 54:805-812, 1999		
		WON <i>et al.</i> , "Tumorigenicity of Mouse Thymoma is Suppressed by Soluble Type II Transforming Growth Factor $\beta$ Receptor Therapy," <i>Cancer Res.</i> 59:1273-1277, 1999		
		YANG <i>et al.</i> , "Lifetime Exposure to a Soluble TGF- $\beta$ Antagonist Protects Mice Against Metastasis without Adverse Side Effects," <i>J. Clin. Invest.</i> 109(12):1607-1615, 2002		
		YIN <i>et al.</i> , "TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development," <i>J. Clin. Invest.</i> 103(2):197-206, 1999		
		ZHENG <i>et al.</i> , "Recombinant Soluble Transforming Growth Factor $\beta$ Type II Receptor Ameliorates Radiation Enteropathy in Mice," <i>Gastroenterol.</i> 119:1286-1296, 2000		
		R&D Systems, Recombinant Human TGF- $\beta$ sRII/Fc Chimera, 2000 (product information sheet, catalog No. 341-BR)		
		R&D Systems, Recombinant Mouse TGF- $\beta$ RII/Fc Chimera, 2000 (product information sheet, catalog No. 532-R2)		

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	